SG11201607623XA - Preparation containing tetracyclic compound at high dose - Google Patents

Preparation containing tetracyclic compound at high dose

Info

Publication number
SG11201607623XA
SG11201607623XA SG11201607623XA SG11201607623XA SG11201607623XA SG 11201607623X A SG11201607623X A SG 11201607623XA SG 11201607623X A SG11201607623X A SG 11201607623XA SG 11201607623X A SG11201607623X A SG 11201607623XA SG 11201607623X A SG11201607623X A SG 11201607623XA
Authority
SG
Singapore
Prior art keywords
high dose
preparation containing
tetracyclic compound
containing tetracyclic
compound
Prior art date
Application number
SG11201607623XA
Other languages
English (en)
Inventor
Takashi Tomimatsu
Kensuke Okazaki
Yumi Ogawa
Takahiro Yamamura
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54332608&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201607623X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of SG11201607623XA publication Critical patent/SG11201607623XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11201607623XA 2014-04-25 2015-04-24 Preparation containing tetracyclic compound at high dose SG11201607623XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014092101 2014-04-25
PCT/JP2015/062520 WO2015163448A1 (ja) 2014-04-25 2015-04-24 ４環性化合物を高用量含有する製剤

Publications (1)

Publication Number Publication Date
SG11201607623XA true SG11201607623XA (en) 2016-11-29

Family

ID=54332608

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201607623XA SG11201607623XA (en) 2014-04-25 2015-04-24 Preparation containing tetracyclic compound at high dose
SG10202009484WA SG10202009484WA (en) 2014-04-25 2015-04-24 Preparation containing tetracyclic compound at high dose

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202009484WA SG10202009484WA (en) 2014-04-25 2015-04-24 Preparation containing tetracyclic compound at high dose

Country Status (17)

Country Link
US (4) US10350214B2 (ko)
EP (1) EP3135287A4 (ko)
JP (2) JP5859712B1 (ko)
KR (2) KR102412321B1 (ko)
CN (2) CN113975243A (ko)
AR (1) AR100187A1 (ko)
AU (2) AU2015250574B2 (ko)
BR (1) BR112016021206B1 (ko)
CA (2) CA3140565C (ko)
IL (2) IL248363B (ko)
MX (2) MX2016013809A (ko)
MY (1) MY189913A (ko)
RU (2) RU2724056C2 (ko)
SG (2) SG11201607623XA (ko)
TW (3) TWI831128B (ko)
WO (1) WO2015163448A1 (ko)
ZA (1) ZA201606447B (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ597477A (en) * 2009-06-10 2014-03-28 Chugai Pharmaceutical Co Ltd Tetracyclic compounds
CN103052386B (zh) 2010-08-20 2016-03-02 中外制药株式会社 含有四环化合物的组合物
SG10201704588XA (en) 2012-09-25 2017-07-28 Chugai Pharmaceutical Co Ltd Ret inhibitor
TW201536293A (zh) 2013-07-18 2015-10-01 Taiho Pharmaceutical Co Ltd 對ｆｇｆｒ抑制劑具耐受性之癌的治療藥
DK3023100T3 (da) 2013-07-18 2019-05-27 Taiho Pharmaceutical Co Ltd Antitumorlægemiddel til intermitterende administration af fgfr-hæmmer
AR100187A1 (es) 2014-04-25 2016-09-14 Chugai Pharmaceutical Co Ltd Composición farmacéutica que contiene un inhibidor de alk (quinasa de linfoma anaplásico)
TWI831347B (zh) 2014-08-08 2024-02-01 日商中外製藥股份有限公司 包含４環性化合物的非晶質體之固體分散體及製劑
KR102584344B1 (ko) 2015-01-16 2023-09-27 추가이 세이야쿠 가부시키가이샤 병용 의약
MX2017012568A (es) 2015-03-31 2018-01-25 Taiho Pharmaceutical Co Ltd Cristal del compuesto alquinil benceno 3,5-disustituido.
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
AU2017226389B2 (en) 2016-03-04 2023-02-02 Taiho Pharmaceutical Co., Ltd. Preparation and composition for treatment of malignant tumors
AU2018256998B2 (en) * 2017-04-28 2023-11-09 Astellas Pharma Inc. Pharmaceutical composition for oral administration comprising
EP3769765B1 (en) 2018-03-19 2024-04-17 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition including sodium alkyl sulfate
BR112020025499A2 (pt) * 2018-06-29 2021-03-09 Chugai Seiyaku Kabushiki Kaisha Composição farmacêutica que compreende agente básico pouco solúvel
TWI825163B (zh) 2018-09-04 2023-12-11 日商中外製藥股份有限公司 四環性化合物的製造方法
AR121187A1 (es) 2019-12-27 2022-04-27 Chugai Pharmaceutical Co Ltd Método para clasificar, evaluar o fabricar lauril sulfato de sodio de materia prima o formulación farmacéutica que lo contiene
WO2021134647A1 (zh) * 2019-12-31 2021-07-08 广州帝奇医药技术有限公司 一种持续释放组合物及其制备方法
WO2022163794A1 (ja) 2021-01-29 2022-08-04 中外製薬株式会社 小児がん治療用医薬組成物
WO2023074785A1 (ja) * 2021-10-28 2023-05-04 中外製薬株式会社 シロップ剤

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4918630B1 (ko) 1970-07-29 1974-05-11
JPH0667840B2 (ja) * 1988-11-30 1994-08-31 萬有製薬株式会社 Ｎｂ―８１８の易吸収性製剤
US5028433A (en) 1988-11-30 1991-07-02 Banyu Pharmaceutical Co., Ltd. Readily absorbable drug formulation of NB-818
JPH0892090A (ja) 1994-07-26 1996-04-09 Tanabe Seiyaku Co Ltd 医薬組成物
EP0695755B1 (en) 1994-08-04 1998-10-21 F. Hoffmann-La Roche AG Pyrrolocarbazole
JPH09202728A (ja) * 1995-12-11 1997-08-05 Hisamitsu Pharmaceut Co Inc 固形製剤
IL126762A0 (en) 1996-05-01 1999-08-17 Lilly Co Eli Halo-substituted protein kinase c inhibitors
WO2000069856A1 (en) 1999-05-14 2000-11-23 The Australian National University Compounds and therapeutic methods
JP4334869B2 (ja) 2000-12-01 2009-09-30 協和発酵キリン株式会社 溶解性または経口吸収性の改善された組成物
GB0030417D0 (en) 2000-12-13 2001-01-24 Pharma Mar Sa An anticancer lead compound isolated from a New Zealand ascidian
FR2841138B1 (fr) 2002-06-25 2005-02-25 Cll Pharma Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation
US7807197B2 (en) 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
AU2004258801A1 (en) 2003-02-28 2005-02-03 Inotek Pharmaceuticals Corporation Tetracyclic Benzamide Derivatives and methods of use thereof
DK1454992T3 (da) 2003-03-07 2006-10-02 Ist Naz Stud Cura Dei Tumori Anaplastisk lymfomakinaseassay, reagenser og sammensætninger deraf
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US7872014B2 (en) 2003-07-23 2011-01-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US7378414B2 (en) 2003-08-25 2008-05-27 Abbott Laboratories Anti-infective agents
WO2005035516A1 (ja) 2003-10-10 2005-04-21 Ono Pharmaceutical Co., Ltd. 新規縮合複素環化合物およびその用途
EP1687305B1 (en) 2003-11-21 2008-07-09 Novartis AG 1h-imidazoquinoline derivatives as protein kinase inhibitors
CN100548986C (zh) 2003-12-12 2009-10-14 默克弗罗斯特加拿大有限公司 组织蛋白酶半胱氨酸蛋白酶抑制剂
TW200609215A (en) 2004-03-19 2006-03-16 Speedel Experimenta Ag Organic compounds
US7973061B2 (en) 2004-03-31 2011-07-05 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
UA87153C2 (ru) 2004-08-26 2009-06-25 Пфайзер Инк. Энантиомерно чистые аминогетероарильные соединения как ингибиторы протеинкиназы
US7091202B2 (en) 2004-09-15 2006-08-15 Bristol-Myers Squibb Company 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators
GB0517329D0 (en) 2005-08-25 2005-10-05 Merck Sharp & Dohme Stimulation of neurogenesis
KR20080056288A (ko) 2005-11-07 2008-06-20 아이알엠 엘엘씨 Ｐｐａｒ 조절제로서의 화합물 및 조성물
US8217057B2 (en) 2005-12-05 2012-07-10 Pfizer Inc. Polymorphs of a c-MET/HGFR inhibitor
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
CA2663451A1 (en) * 2006-09-14 2008-03-20 Astellas Pharma Inc. Rapidly disintegrating tablets in buccal cavity and manufacturing method thereof
CA2598893C (en) 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
EP1914240B1 (en) 2006-10-11 2009-12-02 Astellas Pharma Inc. EML4-ALK fusion gene
CA2669111C (en) 2006-10-23 2016-04-12 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
CN101687873A (zh) 2007-04-17 2010-03-31 百时美施贵宝公司 具有稠合杂环的11β-羟基类固醇Ⅰ型脱氢酶抑制剂
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
JP5506674B2 (ja) 2007-07-20 2014-05-28 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤として活性な置換インダゾール誘導体
CA2932121A1 (en) 2007-11-30 2009-06-11 Newlink Genetics Corporation Ido inhibitors
US20090214648A1 (en) * 2008-02-15 2009-08-27 Malathi Kandakatla Pharmaceutical formulations comprising ibuprofen and diphenhydramine
US20110038898A1 (en) 2008-03-13 2011-02-17 Shuichi Yada Dissolution properties of drug products containing olmesartan medoxomil
JP4707073B2 (ja) * 2008-09-30 2011-06-22 アステラス製薬株式会社 アトルバスタチン経口投与用粒子状医薬組成物
AU2010244218B2 (en) 2009-05-07 2012-07-19 Astrazeneca Ab Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
NZ597477A (en) 2009-06-10 2014-03-28 Chugai Pharmaceutical Co Ltd Tetracyclic compounds
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
US20110311625A1 (en) * 2010-06-14 2011-12-22 Amruth Gowda Doddaveerappa Solid dosage forms of fenofibrate
CN103052386B (zh) * 2010-08-20 2016-03-02 中外制药株式会社 含有四环化合物的组合物
TWI564008B (zh) 2010-09-30 2017-01-01 鹽野義製藥股份有限公司 難溶性藥物之溶解性改善製劑
JP5006987B2 (ja) 2010-11-22 2012-08-22 中外製薬株式会社 ４環性化合物を含む医薬
WO2012138532A2 (en) * 2011-04-06 2012-10-11 Dow Global Technologies Llc Process for producing cellulose derivatives of high bulk density and good flowability
NZ630560A (en) * 2012-04-04 2016-11-25 Teva Pharmaceuticals Int Gmbh Pharmaceutical compositions for combination therapy
SG10201704588XA (en) 2012-09-25 2017-07-28 Chugai Pharmaceutical Co Ltd Ret inhibitor
EP3044593A4 (en) * 2013-09-09 2017-05-17 Triact Therapeutics, Inc. Cancer therapy
JP6873698B2 (ja) 2014-04-25 2021-05-19 中外製薬株式会社 ４環性化合物の新規結晶
AR100187A1 (es) 2014-04-25 2016-09-14 Chugai Pharmaceutical Co Ltd Composición farmacéutica que contiene un inhibidor de alk (quinasa de linfoma anaplásico)
CA2942186C (en) 2014-06-18 2023-06-27 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising non-ionic surfactants
TWI831347B (zh) 2014-08-08 2024-02-01 日商中外製藥股份有限公司 包含４環性化合物的非晶質體之固體分散體及製劑

Also Published As

Publication number Publication date
ZA201606447B (en) 2019-09-25
US11433076B2 (en) 2022-09-06
SG10202009484WA (en) 2020-11-27
TW201622706A (zh) 2016-07-01
AU2015250574B2 (en) 2020-07-16
TW202114693A (zh) 2021-04-16
JP2016104762A (ja) 2016-06-09
KR102478887B1 (ko) 2022-12-16
MX2021012300A (es) 2021-11-12
RU2020119391A (ru) 2020-07-03
CA3140565A1 (en) 2015-10-29
KR20220087583A (ko) 2022-06-24
KR102412321B1 (ko) 2022-06-22
BR112016021206B1 (pt) 2022-07-12
CA2946518A1 (en) 2015-10-29
AU2020230293A1 (en) 2020-10-01
US20230105990A1 (en) 2023-04-06
AR100187A1 (es) 2016-09-14
RU2016145057A (ru) 2018-05-28
IL283152B1 (en) 2023-01-01
MX2016013809A (es) 2017-03-09
IL248363A0 (en) 2016-11-30
BR112016021206A2 (ko) 2017-08-15
US20220378800A1 (en) 2022-12-01
JP5859712B1 (ja) 2016-02-10
CN113975243A (zh) 2022-01-28
TWI720943B (zh) 2021-03-11
NZ763604A (en) 2023-09-29
EP3135287A4 (en) 2018-01-03
TWI771839B (zh) 2022-07-21
AU2015250574A1 (en) 2016-11-24
CA3140565C (en) 2022-10-11
IL248363B (en) 2021-05-31
KR20160146800A (ko) 2016-12-21
NZ724713A (en) 2023-09-29
JP6129942B2 (ja) 2017-05-17
TWI831128B (zh) 2024-02-01
MY189913A (en) 2022-03-21
US20170035773A1 (en) 2017-02-09
IL283152A (en) 2021-06-30
JPWO2015163448A1 (ja) 2017-04-20
TW202235088A (zh) 2022-09-16
RU2016145057A3 (ko) 2018-11-09
AU2020230293B2 (en) 2021-07-22
IL283152B2 (en) 2023-05-01
US20200038407A1 (en) 2020-02-06
WO2015163448A1 (ja) 2015-10-29
US10350214B2 (en) 2019-07-16
RU2724056C2 (ru) 2020-06-19
CN106456651A (zh) 2017-02-22
EP3135287A1 (en) 2017-03-01
CA2946518C (en) 2022-07-26

Similar Documents

Publication Publication Date Title
ZA201606447B (en) Preparation containing tetracyclic compound at high dose
IL249181A0 (en) Compounds containing a self-group as a target
GB201419579D0 (en) Pharmaceutical compound
GB201414730D0 (en) Pharmaceutical compound
GB201509443D0 (en) Seed preparation
IL246447A0 (en) A pharmaceutical preparation containing a pyridylaminoacetic acid compound
GB201415569D0 (en) Therapeutic Compounds
HK1256671A1 (zh) 螺環化合物
FI3363428T3 (fi) Perfuusioannosmuoto
HUE039338T2 (hu) Szcintillátor
GB201416273D0 (en) Therapeutic compounds
HK1232121A1 (zh) 作為抗氧化治療的富勒烯化合物
IL249907A0 (en) Tricyclic substances containing a triazole ring
SG11201702334SA (en) External preparation composition containing s-flurbiprofen
ZA201500995B (en) Low dose pharmaceutical composition
HK1254378A1 (zh) [(2-乙氧基-5-反式-1-丙烯-1-基)-苯氧基]封端化合物
ZA201800217B (en) Novel dosage regimen tiacumicin compound
HK1219664A1 (en) Dosage form containing fungal components
GB201520189D0 (en) Compound for use
GB201419570D0 (en) Pharmaceutical compound
GB201411215D0 (en) Pharmaceutical compound
GB201416462D0 (en) Compound for use
GB201409405D0 (en) Therapeutic compounds
GB201406154D0 (en) Pharmaceutical compound
GB201407122D0 (en) Therapeutic compounds